Evaluation of WO2012078210--development process for the preparation of a DP2 receptor antagonist; Ironwood's first
1Norman Consulting, 18 Pink Lane, Burnham, Bucks, SL1 8JW, UK. peter.norman2@btinternet.com
Expert Opinion on Therapeutic Patents
|July 21, 2012
Abstract:
This application claims processes for the preparation of a series of pyrrole-based DP2 receptor antagonists, in particular 2-[3-cyano-2,5-dimethyl-4-[(2-pyrrolidin-1-ylsulfonylphenyl)methyl]pyrrol-1-yl]acetic acid. The nature of the filing points to this compound being a development compound and it may be IW-1221 which has previously been identified as a DP2 antagonist.
More Related Videos
Related Concept Videos
Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...


